Pharmapremia Oncology Success Rates Scorecard

DESCRIPTION

Over the past five years, oncology drug development has increased dramatically as a proverbial arms-race accelerated into the immune-oncology space. Some of the biggest names in Pharma began development internally, and scoured the globe for in-licensing and acquisition candidates to stake their claim to the next-generation of cancer standard of care.

With Oncology drug development making up over 30% of all industry-sponsored trials, growing at a 7.8% annually since 2005, it is prudent to step back and review just how successful this increased development has been. Some of the key names in Pharma – Roche/Genentech, Bristol-Myers, Merck, AbbVie and more, have all had widely varying success in the field of oncology.

The companies for which we provided detailed analysis include:

  • Roche Holding AG
  • Novartis
  • Eli Lilly & Company
  • Pfizer
  • AstraZeneca PLC
  • Sanofi
  • Bristol-Myers Squibb Company
  • Amgen, Inc.
  • Celgene Corporation
  • AbbVie, Inc.
  • Merck & Co., Inc.

In this analysis, we break down key metrics of oncology success rates by disease group (Hematologic vs. Solids), by drug class (New Molecular Entity vs. Biologic) and on a company-by-company basis…

  • See which top-pharma has the highest Phase II oncology candidate success rate. Find out not only their historical success rates, but review a deep-dive into what compounds and programs are driving those results for the top performing companies.
  • Understand what candidates make or break a pipeline, and who ‘fails fast’, potentially saving millions on late-stage clinical development costs.
  • Compare success rates by New Molecular Entity and Biologic.
  • Discover the impact that the acquisitions of Medivation and Pharmacyclics had on the success rates of Pfizer and AbbVie respectively.
  • Learn just how important Biomarker selection is in clinical success rates.

Table of Contents

•   Pharmapremia Background + Success Rate Methodology
•   Oncology Success Rates presented as a Complete Disease Area and Split Between Solid Tumor and Hematologic Malignancy Subsets
•   Company-Specific Oncology Success Rates
•   Company-Specific Solid Tumor Success Rates
– Deep-dive analysis into the success and failures of the top four companies
•   Company-Specific Hematologic Malignancy Success Rate
– Deep-dive analysis into the successes and failures of the three key companies
•   Assessment of the Impact that the Medivation Acquisition has had on Pfizer’s Clinical Success Rates
– This analysis in comparison to the Impact that a Medivation Acquisition would have had on Sanofi’s Clinical Success Rates
•   Assessment of the Impact that the Pharmacylic Acquisition had on Abbvie’s Clinical Success Rates
•   Oncology Success rates: Comparing NME development with that of Biologics across the Industry
•   Oncology Success Rates: Comparing New Molecular Entity development with that of Biologics By Company
•   Oncology Success Rate Changes over Time – Comparison of 2006-10 vs. 2011-15 Cohorts
•   Appendix
– Data Details
– Abbreviations Used

Number of pages: 30
Formats: PDF
Price: $25,000

To Procure or for More Info, Please Write us at: info@omensol.com

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Create a free website or blog at WordPress.com.

Up ↑